Published summary: 2026-03-07
Where the evidence converges
Meta-analysis of 58 RCTs in adults 50+ found cannabinoid medicines increase common side effects dose-dependently but do not significantly increase serious adverse events, withdrawals, or deaths
Strong evidence · 2 studies
RCT populations may be healthier than real-world older cannabis users. Most trials were relatively short-term. The wide confidence intervals for some outcomes reflect heterogeneity. CBD-only medicines
Multicenter RCT finds dronabinol (THC) safely and effectively reduces Alzheimer's agitation over 3 weeks with a medium effect size and no cognitive decline
Strong evidence · 1 studies
Only 3 weeks duration. Most participants were on concomitant psychotropics. Moderate sample size. One of two primary outcomes did not reach significance. Long-term safety and efficacy unknown.
Where questions remain
Among nearly 30,000 adults over 50, marijuana-only users had 1
Moderate evidence · 13 studies
Cross-sectional design cannot determine whether marijuana use contributes to depression or whether depressed older adults are more likely to use marijuana. Self-reported drug use may be underreported.
Cannabis use among Americans over 50 surged between 2006-2013, with a 250% increase among those 65+, while most older users perceived little to no risk
Moderate evidence · 13 studies
Cross-sectional survey design. Self-reported cannabis use may be underreported due to stigma. Cannot distinguish medical from recreational use. Survey excludes institutionalized populations (nursing h
Essay examining rising cannabis use among Americans 65+, arguing cannabis may be a viable alternative to opioids for pain but calling for more research on this understudied population
Moderate evidence · 13 studies
This is an essay/commentary rather than a systematic review or original research. It does not present new data and relies on existing literature that the authors acknowledge is insufficient for the ol
Review of herbal medicine use in elderly IBD patients identifies cannabis among many supplements with potential drug-herb interactions, emphasizing the need for provider awareness
Moderate evidence · 13 studies
Narrative review without systematic search methodology. Cannabis was one of many herbs discussed, and the depth of cannabis-specific interaction data was limited. Much of the interaction evidence is t
Research gaps
- Long-term prospective studies tracking outcomes over 5+ years are largely absent from the literature.
- Research on diverse populations (different ages, ethnicities, and medical backgrounds) remains limited.
Key studies
Cannabinoid Medicines Are Generally Safe for Older Adults, With Dose-Dependent Side Effects
Older adults are the fastest-growing demographic of cannabinoid medicine users, yet most safety data comes from younger populations. This meta-analysis specifically addresses the 50+ age group, providing age-appropriate safety data for clinical decision-making.
THC Drug Dronabinol Safely Reduced Agitation in Alzheimer's Patients in Clinical Trial
Agitation in Alzheimer's is extremely common and distressing, and current treatments have limited effectiveness with serious safety concerns including increased mortality risk. Dronabinol showed clinically meaningful agitation reduction with a favorable safety profile.
Low-Dose THC-CBD Extract Showed Cognitive Benefit in 26-Week Alzheimer's Trial
Alzheimer's has very few effective treatments. A 26-week trial showing cognitive benefit with a remarkably low cannabinoid dose could open a new treatment avenue.
Low-Dose CBD Was Safe for Parkinson's Patients but Showed Limited Cognitive Benefit
This is one of the few rigorous RCTs testing CBD in Parkinson's disease. While the results are largely negative at this dose, the safety data supports exploration of higher doses in future trials.
Older adults showed selective cognitive effects after smoking cannabis in naturalistic lab study
Adults over 65 are the fastest-growing group of cannabis users, yet almost no research examines acute effects in this population. This study provides rare data showing that cognitive impacts may be more selective than expected, affecting processing speed and executive function but not necessarily me
Cannabis Mouth Spray Did Not Increase Calorie Intake in Older Adults With Poor Appetite
Anorexia of aging is a significant problem with limited effective treatments. While cannabis has long been associated with appetite stimulation ("the munchies"), this RCT found no meaningful effect in older adults with poor appetite at the tested dose and formulation.
How the research developed
Pre-2000
1 studies published. Predominantly observational and review studies.
2015–2019
13 studies published. Predominantly observational and review studies.
2020–present
92 studies published. Includes 1 meta-analyses, 6 RCTs, 12 strong-evidence studies.
How this summary was assembled
This consensus synthesizes 106 peer-reviewed studies: 1 meta-analyses (1%), 6 randomized controlled trials (6%), 35 observational studies (33%), 19 reviews (18%), 1 case studies (1%), 44 other study types (42%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.
These counts describe the source summary at publication. They may differ from the current library.